Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q2
Sell
-133,500
Closed -$15.2M 123
2024
Q1
$15.2M Sell
133,500
-30,990
-19% -$3.55M 0.72% 49
2023
Q4
$18.1M Buy
164,490
+51,900
+46% +$5.19M 1.26% 32
2023
Q3
$10.9M Sell
112,590
-98,300
-47% -$10.3M 0.74% 62
2023
Q2
$23M Sell
210,890
-11,400
-5% -$1.22M 1.62% 15
2023
Q1
$22.5M Buy
222,290
+110,060
+98% +$11.6M 1.33% 30
2022
Q4
$12.3M Sell
112,230
-89,300
-44% -$9.25M 0.66% 65
2022
Q3
$19.5M Buy
201,530
+8,900
+5% +$949K 1.14% 42
2022
Q2
$20.9M Hold
192,630
1.26% 36
2022
Q1
$22.8M Sell
192,630
-87,100
-31% -$10.8M 1.15% 39
2021
Q4
$39.4M Sell
279,730
-900
-0.3% -$115K 1.82% 13
2021
Q3
$33.2M Hold
280,630
1.72% 14
2021
Q2
$32.5M Buy
280,630
+261,900
+1,398% +$30.5M 1.55% 20
2021
Q1
$2.25M Sell
18,730
-156,700
-89% -$18.6M 0.1% 77
2020
Q4
$19.2M Buy
+175,430
New +$19.1M 0.98% 56
2016
Q2
Sell
-549
Closed -$23K 110
2016
Q1
$23K Hold
549
﹤0.01% 111
2015
Q4
$25K Buy
+549
New +$24.2K ﹤0.01% 128

Other funds holding ABT

Payden & Rygel's ABT Position: Q2 2024 in Review

Payden & Rygel sold out of Abbott (ABT) in Q2 2024, closing a stake of 133,500 shares — an estimated $15.2M sold.

Payden & Rygel first reported a position in ABT in Q4 2015 and held it in 16 quarters. The position peaked at $39.4M in Q4 2021. 2,861 funds tracked by Wall St. Rank hold ABT as of Q2 2024.

  • Payden & Rygel reported no remaining Abbott position as of Q2 2024 after selling out during the quarter.
  • Payden & Rygel sold 133,500 Abbott shares in Q2 2024, an estimated $15.2M.
  • Payden & Rygel first reported a position in Abbott in Q4 2015 and held it in 16 quarters.
  • Payden & Rygel's Abbott position peaked at $39.4M in Q4 2021.
  • 2,861 funds tracked by Wall St. Rank held Abbott as of Q2 2024.

Based on Payden & Rygel's 13F filing for Q2 2024, filed 7 Oct 2024.